Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Non-Current Debt (2016 - 2019)

Historic Non-Current Debt for Fate Therapeutics (FATE) over the last 8 years, with Q2 2019 value amounting to $9.5 million.

  • Fate Therapeutics' Non-Current Debt fell 2622.52% to $9.5 million in Q2 2019 from the same period last year, while for Jun 2019 it was $9.5 million, marking a year-over-year decrease of 2622.52%. This contributed to the annual value of $12.4 million for FY2018, which is 1595.08% down from last year.
  • According to the latest figures from Q2 2019, Fate Therapeutics' Non-Current Debt is $9.5 million, which was down 2622.52% from $11.0 million recorded in Q1 2019.
  • Fate Therapeutics' Non-Current Debt's 5-year high stood at $16.4 million during Q1 2015, with a 5-year trough of $1.1 million in Q1 2017.
  • Its 5-year average for Non-Current Debt is $10.3 million, with a median of $11.3 million in 2018.
  • Per our database at Business Quant, Fate Therapeutics' Non-Current Debt crashed by 8757.47% in 2017 and then surged by 120148.01% in 2018.
  • Quarter analysis of 5 years shows Fate Therapeutics' Non-Current Debt stood at $10.7 million in 2015, then tumbled by 76.6% to $2.5 million in 2016, then soared by 492.08% to $14.8 million in 2017, then fell by 15.95% to $12.4 million in 2018, then decreased by 23.92% to $9.5 million in 2019.
  • Its Non-Current Debt stands at $9.5 million for Q2 2019, versus $11.0 million for Q1 2019 and $12.4 million for Q4 2018.